BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 16496933)

  • 1. CCNU in the treatment of canine epitheliotropic lymphoma.
    Williams LE; Rassnick KM; Power HT; Lana SE; Morrison-Collister KE; Hansen K; Johnson JL
    J Vet Intern Med; 2006; 20(1):136-43. PubMed ID: 16496933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response of canine cutaneous epitheliotropic lymphoma to lomustine (CCNU): a retrospective study of 46 cases (1999-2004).
    Risbon RE; de Lorimier LP; Skorupski K; Burgess KE; Bergman PJ; Carreras J; Hahn K; Leblanc A; Turek M; Impellizeri J; Fred R; Wojcieszyn JW; Drobatz K; Clifford CA
    J Vet Intern Med; 2006; 20(6):1389-97. PubMed ID: 17186855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of canine mast cell tumors with CCNU (lomustine).
    Rassnick KM; Moore AS; Williams LE; London CA; Kintzer PP; Engler SJ; Cotter SM
    J Vet Intern Med; 1999; 13(6):601-5. PubMed ID: 10587263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lomustine (CCNU) for the treatment of resistant lymphoma in dogs.
    Moore AS; London CA; Wood CA; Williams LE; Cotter SM; L'Heureux DA; Frimberger AE
    J Vet Intern Med; 1999; 13(5):395-8. PubMed ID: 10499719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is CCNU (lomustine) valuable for treatment of cutaneous epitheliotropic lymphoma in dogs? A critically appraised topic.
    Laprais A; Olivry T
    BMC Vet Res; 2017 Feb; 13(1):61. PubMed ID: 28222789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of CCNU and DTIC chemotherapy for treatment of resistant lymphoma in dogs.
    Flory AB; Rassnick KM; Al-Sarraf R; Bailey DB; Balkman CE; Kiselow MA; Autio K
    J Vet Intern Med; 2008; 22(1):164-71. PubMed ID: 18289305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CCNU (lomustine) toxicity in dogs: a retrospective study (2002-07).
    Heading KL; Brockley LK; Bennett PF
    Aust Vet J; 2011 Apr; 89(4):109-16. PubMed ID: 21418164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant CCNU (lomustine) and prednisone chemotherapy for dogs with incompletely excised grade 2 mast cell tumors.
    Hosoya K; Kisseberth WC; Alvarez FJ; Lara-Garcia A; Beamer G; Stromberg PC; Couto CG
    J Am Anim Hosp Assoc; 2009; 45(1):14-8. PubMed ID: 19122059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tolerability of lomustine in combination with cyclophosphamide in dogs with lymphoma.
    Rassnick KM; Bailey DB; Malone EK; Flory AB; Kiselow MA; Intile JL
    J Am Anim Hosp Assoc; 2014; 50(3):167-73. PubMed ID: 24659727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatotoxicity associated with CCNU (lomustine) chemotherapy in dogs.
    Kristal O; Rassnick KM; Gliatto JM; Northrup NC; Chretin JD; Morrison-Collister K; Cotter SM; Moore AS
    J Vet Intern Med; 2004; 18(1):75-80. PubMed ID: 14765735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Updates on the management of canine epitheliotropic cutaneous T-cell lymphoma.
    de Lorimier LP
    Vet Clin North Am Small Anim Pract; 2006 Jan; 36(1):213-28, viii-ix. PubMed ID: 16364786
    [No Abstract]   [Full Text] [Related]  

  • 12. Canine cutaneous epitheliotropic T-cell lymphoma: a review.
    Fontaine J; Bovens C; Bettenay S; Mueller RS
    Vet Comp Oncol; 2009 Mar; 7(1):1-14. PubMed ID: 19222826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tolerability of metronomic administration of lomustine in dogs with cancer.
    Tripp CD; Fidel J; Anderson CL; Patrick M; Pratt C; Sellon R; Bryan JN
    J Vet Intern Med; 2011; 25(2):278-84. PubMed ID: 21314727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors associated with the onset of lomustine-induced neutropenia in tumour-bearing dogs.
    Treggiari E; Cossu G; Valenti P; Taylor A
    Vet Comp Oncol; 2022 Sep; 20(3):577-586. PubMed ID: 35249267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epitheliotropic cutaneous lymphoma (mycosis fungoides) in a dog.
    Bhang DH; Choi US; Kim MK; Choi EH; Kang MS; Hwang CY; Kim DY; Youn HY; Lee CW
    J Vet Sci; 2006 Mar; 7(1):97-9. PubMed ID: 16434861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CCNU for the treatment of dogs with histiocytic sarcoma.
    Skorupski KA; Clifford CA; Paoloni MC; Lara-Garcia A; Barber L; Kent MS; LeBlanc AK; Sabhlok A; Mauldin EA; Shofer FS; Couto CG; Sørenmo KU
    J Vet Intern Med; 2007; 21(1):121-6. PubMed ID: 17338159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lomustine for treatment of mast cell tumors in cats: 38 cases (1999-2005).
    Rassnick KM; Williams LE; Kristal O; Al-Sarraf R; Baez JL; Zwahlen CH; Dank G
    J Am Vet Med Assoc; 2008 Apr; 232(8):1200-5. PubMed ID: 18412534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II, open-label trial of single-agent CCNU in dogs with previously untreated histiocytic sarcoma.
    Rassnick KM; Moore AS; Russell DS; Northrup NC; Kristal O; Bailey DB; Flory AB; Kiselow MA; Intile JL
    J Vet Intern Med; 2010; 24(6):1528-31. PubMed ID: 21155191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I evaluation of CCNU (lomustine) in tumor-bearing cats.
    Rassnick KM; Gieger TL; Williams LE; Ruslander DM; Northrup NC; Kristal O; Myers NC; Moore AS
    J Vet Intern Med; 2001; 15(3):196-9. PubMed ID: 11380027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of lomustine (CCNU) in a case of cutaneous equine lymphoma.
    Doyle AJ; MacDonald VS; Bourque A
    Can Vet J; 2013 Dec; 54(12):1137-41. PubMed ID: 24293673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.